Charles River Laboratories International Inc(CRL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -4.85 | Insider Own | 1.12% | Shs Outstand | 47.7M | Perf Week | 13.75% |
| Market Cap | 17.13B | Forward P/E | 28.04 | EPS next Y | 12.45% | Insider Trans | -26.54% | Shs Float | 47.2M | Perf Month | 21.81% |
| Enterprise Value | 20.00B | PEG | 2.4 | EPS next Q | 2.97 | Inst Own | 123.13% | Short Float | 6% | Perf Quarter | 52.83% |
| Income | -0.24B | P/S | 4.28 | EPS this Y | 10.69% | Inst Trans | -2.01% | Short Ratio | 2.8 | Perf Half Y | 115.14% |
| Sales | 4.00B | P/B | 6.03 | EPS next 5Y | 11.7% | ROA | -3.16% | Short Interest | 2.83M | Perf YTD | 79.89% |
| Book/sh | 59.5 | P/C | 79.14 | EPS past 3/5Y | - | ROE | -7.7% | 52W High | 0.3% ($357.77) | Perf Year | 83.76% |
| Cash/sh | 4.53 | P/FCF | 46.22 | Sales past 3/5Y | 0.33% 6.55% | ROIC | -4.06% | 52W Low | 145.45% ($146.20) | Perf 3Y | 107.91% |
| Dividend Est. | - | EV/EBITDA | 23.85 | EPS Y/Y TTM | -268.79% | Gross Margin | 32.63% | Volatility(W/M) | 5.08% 4.29% | Perf 5Y | -16.56% |
| Dividend TTM | - | EV/Sales | 5 | Sales Y/Y TTM | -0.74% | Oper. Margin | 13.51% | ATR (14) | 13.07 | Perf 10Y | 369.19% |
| Dividend Ex-Date | - | Quick Ratio | 1.04 | EPS Q/Q | -102.91% | Profit Margin | -5.96% | RSI (14) | 76.79 | Recom | 1.85 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | -2.72% | SMA20 | 14.67% ($312.93) | Beta | 1.39 | Target Price | $331.29 |
| Payout | - | Debt/Eq | 1.07 | Earnings | 2026/11/4 | SMA50 | 20.85% ($296.93) | Rel Volume | 1.15 | Prev Close | $357.27 |
| Employees | 19700 | LT Debt/Eq | 1.07 | EPS/Sales Surpr. | 10.13% 2.75% | SMA200 | 63.48% ($219.5) | Avg Volume(3M) | 1.01M | Price | $358.84 |
| IPO | 2000/6/23 | Option/Short | Yes/Yes | Trades | 13501 | Volume | 1,159,687 | Change | 0.44% |
A global contract research organization (CRO) that supports the preclinical stage of new drug development. The company supports the entire early-stage research and development process for pharmaceutical and biotech companies, including research models, drug discovery, safety evaluation, and contract manufacturing, and is a healthcare services company with a leading global position in the preclinical CRO field.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
Next earnings report: November 4
7 days to go.
CRL keeps an operating profit but posts a net loss
Of every $100 in sales, $13.51 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $428. Peers typically go for $664. Compared with its own 3-year average, it is 1339% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -16.6%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 123.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #15 of 44 in the industry
Based on market cap of $17B.
GH#12 Guardant Health Inc $24B PER - 
MEDP#13 Medpace Holdings Inc $19B PER 37.4 
RVTY#14 Revvity Inc $18B PER 76.9 CRL#15 Charles River Laboratories International Inc $17B PER - 
ICLR#16 Icon Plc $14B PER 332.1 
FAQ
What kind of company is CRL?
CRL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CRL?
The market cap of CRL is approximately $17.1B, ranking 660 within its sector.
What is the 52-week high and low for CRL?
CRL has recorded a 52-week high of $357.77 and a low of $146.20.
